Sorafenib and pegylated interferon-α2b in advanced metastatic melanoma: a multicenter phase II DeCOG trial
Background - The combination of sorafenib, a multikinase inhibitor, and pegylated interferon-α2b (Peg-IFN-α2b) could potentially lead to an improved antitumoral response. Previously, combinations of interferon and sorafenib have been used in renal cell cancer. - Patients and methods - Patients with...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
2011
|
| In: |
Annals of oncology
Year: 2011, Jahrgang: 22, Heft: 7, Pages: 1667-1674 |
| ISSN: | 1569-8041 |
| DOI: | 10.1093/annonc/mdq648 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1093/annonc/mdq648 Verlag, lizenzpflichtig, Volltext: https://www.sciencedirect.com/science/article/pii/S0923753419384455 
|
| Verfasserangaben: | F. Egberts, R. Gutzmer, S. Ugurel, J.C. Becker, U. Trefzer, A. Degen, F. Schenck, L. Frey, T. Wilhelm, J.C. Hassel, D. Schadendorf, E. Livingstone, C. Mauch, C. Garbe, C. Berking, K. Rass, P. Mohr, K.C. Kaehler, M. Weichenthal & A. Hauschild |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1797761374 | ||
| 003 | DE-627 | ||
| 005 | 20230428015100.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 220406s2011 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/annonc/mdq648 |2 doi | |
| 035 | |a (DE-627)1797761374 | ||
| 035 | |a (DE-599)KXP1797761374 | ||
| 035 | |a (OCoLC)1341458518 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Egberts, Friederike |e VerfasserIn |0 (DE-588)1020733594 |0 (DE-627)691326568 |0 (DE-576)361911416 |4 aut | |
| 245 | 1 | 0 | |a Sorafenib and pegylated interferon-α2b in advanced metastatic melanoma |b a multicenter phase II DeCOG trial |c F. Egberts, R. Gutzmer, S. Ugurel, J.C. Becker, U. Trefzer, A. Degen, F. Schenck, L. Frey, T. Wilhelm, J.C. Hassel, D. Schadendorf, E. Livingstone, C. Mauch, C. Garbe, C. Berking, K. Rass, P. Mohr, K.C. Kaehler, M. Weichenthal & A. Hauschild |
| 246 | 3 | 3 | |a Sorafenib and pegylated interferon-alpha2b in advanced metastatic melanoma |
| 264 | 1 | |c 2011 | |
| 300 | |a 8 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Version of Record 6 January 2020 | ||
| 500 | |a Gesehen am 06.04.2022 | ||
| 520 | |a Background - The combination of sorafenib, a multikinase inhibitor, and pegylated interferon-α2b (Peg-IFN-α2b) could potentially lead to an improved antitumoral response. Previously, combinations of interferon and sorafenib have been used in renal cell cancer. - Patients and methods - Patients with stage IV metastatic melanoma and no previous systemic therapies apart from adjuvant immunotherapy received Peg-IFN-α2b 3 μg/kg once per week, and sorafenib 400-mg b.i.d. for a minimum of 8 weeks. The primary study end point was disease control rate (DCR). - Results - Between February 2008 and February 2009, 55 patients were enrolled with a median age of 64 years (20-85). At 8 weeks, 2 patients (3.6%) had a partial response (PR) and 14 patients a stable disease (25.5%), for a DCR of 29.1% in the intention-to-treat (ITT) population. The median progression-free survival in the ITT population was 2.47 months (95% confidence interval 1.22-3.72 months). The toxicity of sorafenib and Peg-IFN-α2b combination was characterized by mainly hematological side-effects, including one treatment-related bleeding complication with a fatal outcome. Other grade 3/4 toxic effects were fatigue and flu-like symptoms. - Conclusion - The combination of sorafenib and Peg-IFN-α2b showed modest clinical activity and some serious side-effects including fatal bleeding complications. | ||
| 650 | 4 | |a metastatic melanoma | |
| 650 | 4 | |a pegylated IFN | |
| 650 | 4 | |a sorafenib | |
| 700 | 1 | |a Gutzmer, R. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Ugurel, S. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Becker, J. C. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Trefzer, U. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Degen, A. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Schenck, F. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Frey, L. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Wilhelm, T. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Hassel, Jessica C. |d 1975- |e VerfasserIn |0 (DE-588)129790702 |0 (DE-627)480399069 |0 (DE-576)29783715X |4 aut | |
| 700 | 1 | |a Schadendorf, D. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Livingstone, E. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Mauch, C. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Garbe, C. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Berking, C. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Rass, K. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Mohr, P. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kaehler, K. C. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Weichenthal, M. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Hauschild, A. |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Annals of oncology |d Amsterdam [u.a.] : Elsevier, 1990 |g 22(2011), 7, Seite 1667-1674 |h Online-Ressource |w (DE-627)320428796 |w (DE-600)2003498-2 |w (DE-576)098134345 |x 1569-8041 |7 nnas |a Sorafenib and pegylated interferon-α2b in advanced metastatic melanoma a multicenter phase II DeCOG trial |
| 773 | 1 | 8 | |g volume:22 |g year:2011 |g number:7 |g pages:1667-1674 |g extent:8 |a Sorafenib and pegylated interferon-α2b in advanced metastatic melanoma a multicenter phase II DeCOG trial |
| 856 | 4 | 0 | |u https://doi.org/10.1093/annonc/mdq648 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://www.sciencedirect.com/science/article/pii/S0923753419384455 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20220406 | ||
| 993 | |a Article | ||
| 994 | |a 2011 | ||
| 998 | |g 129790702 |a Hassel, Jessica C. |m 129790702:Hassel, Jessica C. |d 910000 |d 911300 |e 910000PH129790702 |e 911300PH129790702 |k 0/910000/ |k 1/910000/911300/ |p 10 | ||
| 999 | |a KXP-PPN1797761374 |e 4112510926 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"title":[{"subtitle":"a multicenter phase II DeCOG trial","title":"Sorafenib and pegylated interferon-α2b in advanced metastatic melanoma","title_sort":"Sorafenib and pegylated interferon-α2b in advanced metastatic melanoma"}],"note":["Version of Record 6 January 2020","Gesehen am 06.04.2022"],"type":{"bibl":"article-journal","media":"Online-Ressource"},"language":["eng"],"person":[{"family":"Egberts","role":"aut","given":"Friederike","display":"Egberts, Friederike"},{"display":"Gutzmer, R.","family":"Gutzmer","given":"R.","role":"aut"},{"family":"Ugurel","given":"S.","role":"aut","display":"Ugurel, S."},{"role":"aut","given":"J. C.","family":"Becker","display":"Becker, J. C."},{"family":"Trefzer","role":"aut","given":"U.","display":"Trefzer, U."},{"given":"A.","role":"aut","family":"Degen","display":"Degen, A."},{"role":"aut","given":"F.","family":"Schenck","display":"Schenck, F."},{"display":"Frey, L.","family":"Frey","role":"aut","given":"L."},{"display":"Wilhelm, T.","family":"Wilhelm","role":"aut","given":"T."},{"family":"Hassel","given":"Jessica C.","role":"aut","display":"Hassel, Jessica C."},{"display":"Schadendorf, D.","role":"aut","given":"D.","family":"Schadendorf"},{"display":"Livingstone, E.","given":"E.","role":"aut","family":"Livingstone"},{"display":"Mauch, C.","given":"C.","role":"aut","family":"Mauch"},{"role":"aut","given":"C.","family":"Garbe","display":"Garbe, C."},{"given":"C.","role":"aut","family":"Berking","display":"Berking, C."},{"given":"K.","role":"aut","family":"Rass","display":"Rass, K."},{"given":"P.","role":"aut","family":"Mohr","display":"Mohr, P."},{"display":"Kaehler, K. C.","role":"aut","given":"K. C.","family":"Kaehler"},{"display":"Weichenthal, M.","role":"aut","given":"M.","family":"Weichenthal"},{"family":"Hauschild","role":"aut","given":"A.","display":"Hauschild, A."}],"relHost":[{"part":{"year":"2011","volume":"22","pages":"1667-1674","extent":"8","text":"22(2011), 7, Seite 1667-1674","issue":"7"},"id":{"zdb":["2003498-2"],"issn":["1569-8041"],"eki":["320428796"]},"pubHistory":["1.1990 -"],"corporate":[{"display":"European Society for Medical Oncology","role":"isb"}],"disp":"Sorafenib and pegylated interferon-α2b in advanced metastatic melanoma a multicenter phase II DeCOG trialAnnals of oncology","recId":"320428796","physDesc":[{"extent":"Online-Ressource"}],"title":[{"title_sort":"Annals of oncology","title":"Annals of oncology","subtitle":"official journal of the European Society for Medical Oncology"}],"note":["Gesehen am 12.11.20","Ungezählte Beil.: Supplement"],"language":["eng"],"type":{"bibl":"periodical","media":"Online-Ressource"},"origin":[{"publisher":"Elsevier ; Kluwer ; Oxford Univ. Press","publisherPlace":"Amsterdam [u.a.] ; Dordrecht [u.a.] ; Oxford","dateIssuedKey":"1990","dateIssuedDisp":"1990-"}]}],"origin":[{"dateIssuedDisp":"2011","dateIssuedKey":"2011"}],"recId":"1797761374","physDesc":[{"extent":"8 S."}],"id":{"doi":["10.1093/annonc/mdq648"],"eki":["1797761374"]},"titleAlt":[{"title":"Sorafenib and pegylated interferon-alpha2b in advanced metastatic melanoma"}],"name":{"displayForm":["F. Egberts, R. Gutzmer, S. Ugurel, J.C. Becker, U. Trefzer, A. Degen, F. Schenck, L. Frey, T. Wilhelm, J.C. Hassel, D. Schadendorf, E. Livingstone, C. Mauch, C. Garbe, C. Berking, K. Rass, P. Mohr, K.C. Kaehler, M. Weichenthal & A. Hauschild"]}} | ||
| SRT | |a EGBERTSFRISORAFENIBA2011 | ||